The DSG2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line. Using CRISPR/Cas9-mediated gene disruption, the DSG2 gene??encoding the desmosomal cadherin desmoglein 2??has been targeted to abolish its expression. This polyclonal derivative comprises a heterogeneous pool of cells with various DSG2 knockout alleles, providing a versatile loss-of-function model without clonal selection biases. As a polyclonal knockout product, it is particularly suited for studying the functional consequences of desmoglein 2 disruption in a mixed genetic background, recapitulating the heterogeneity often observed in tumor cell populations.
The parental HT29 cell line is a widely utilized human colon adenocarcinoma epithelial model originally isolated from a 44-year-old female. These cells exhibit typical epithelial morphology, form polarized monolayers, and express characteristic tight junction and adherens junction proteins. HT29 cells are a standard system for investigating intestinal epithelial biology, colorectal cancer progression, and signaling pathways including Wnt/??-catenin, which is constitutively activated due to APC mutations. Their robust growth characteristics and well-characterized signaling landscape make them an ideal host for dissecting the role of desmosomal components in colorectal cancer and epithelial homeostasis.
Desmoglein 2, encoded by DSG2, is a calcium-dependent cadherin and core component of desmosomes that confer mechanical tissue integrity. It directly interacts with plakoglobin (JUP) and plakophilin 2 (PKP2), which link to desmoplakin (DSP) and desmocollin 2 (DSC2) to anchor intermediate filaments. DSG2 expression is regulated by upstream factors including p63, retinoic acid, glucocorticoids, and the Wnt/??-catenin pathway. DSG2 knockout disrupts desmosome assembly, impairing cell adhesion and promoting plakoglobin nuclear translocation, where it may modulate TCF/LEF-mediated Wnt target gene transcription. Concurrently, Rho GTPase activity and cytoskeletal remodeling are altered, collectively driving epithelial-mesenchymal transition (EMT) with characteristic marker changes. Thus, DSG2 loss activates a cascade intersecting with ??-catenin (CTNNB1) signaling and adhesive functions.
In HT29 colorectal adenocarcinoma cells, DSG2 disruption is particularly significant for dissecting the cross-talk between desmosomal adhesion and oncogenic Wnt/??-catenin signaling. With constitutively active ??-catenin due to an APC mutation, further DSG2 loss may potentiate ??-catenin nuclear activity, offering a model to study synergism between junctional disruption and oncogenic pathways. This knockout also enables investigation of desmosomal dysfunction in cancer cell dissemination, metastasis, and barrier loss??hallmarks of advanced carcinoma. Beyond oncology, the cells serve as a surrogate for desmosome-related diseases like ARVC, Naxos disease, and skin fragility. The polyclonal nature supports analysis of phenotypic variability.
This polyclonal knockout product is ideally suited for a broad range of biomedical research applications. Key experimental uses include cell adhesion and aggregation assays to quantitatively measure intercellular cohesion, migration and invasion assays to evaluate metastatic potential, and epithelial barrier integrity assays using transepithelial electrical resistance (TEER) or paracellular flux measurements. Researchers can monitor downstream effects via immunofluorescence staining for desmosomal and adherens junction proteins, Western blotting for EMT markers, and qRT-PCR to profile transcriptional changes in CTNNB1 targets, Wnt effectors, and EMT-associated genes. Co-immunoprecipitation studies can probe altered protein?Cprotein interactions among desmosomal and cytoskeletal components, while phospho-signaling analyses can map pathway activation changes. The DSG2 Knockout HT29 Polyclonal Cells thus constitute a powerful tool for dissecting desmosome biology, cancer metastasis, and drug screening for adhesion-related pathologies. For additional technical information, lot-specific data, and ordering details, please contact Ascent Research.
